First line treatment for type 2 diabetes also reduces the risk of heart disease in patients with type 1 diabetes

According to a new global trial launched by the University of Glasgow (http://www.chemdrug.com/sell/24/), low-cost first-line drugs for type 2 diabetes (http://www.chemdrug.com/) can also reduce the risk of heart disease in patients with type 1 diabetes The results were published yesterday at the 77th scientific conference of the American Diabetes Association (http://www.chemdrug.com/exhibit/) in San Diego and in the lancet - diabetes and endocrinology The results show that metformin has potential beneficial effects on cardiovascular and metabolism in adult patients with long-term type 1 diabetes At present, metformin is recommended to reduce insulin demand and maintain body weight in patients with type 1 diabetes, but the effect of metformin on heart and blood pressure is not clear Heart disease is the most common cause of life expectancy reduction in type 1 diabetes In Scotland, only 15% of adults with type 1 diabetes have been treated with metformin and 8% have only taken it once The removal trial is the largest study on metformin in the treatment of type 1 diabetic patients This study provides significant clinical data support for metformin to potentially reduce the risk of cardiovascular disease development in type 1 diabetic patients "The results of this clinical trial are very important because cardiovascular disease is a major factor in reducing the life expectancy of patients with type 1 diabetes, incidence rate of cardiovascular disease is more than 2 times that of patients without type 1 diabetes," said John Petrie, director of the Research Institute of cardiovascular and Medical Sciences, University of Glasgow Type 1 diabetes is not caused by lifestyle Insulin therapy is needed to control blood sugar and reduce complications, but it can cause weight gain and is associated with high cholesterol This is also one of the reasons that cardiovascular complications still plague type 1 diabetes patients " John Petrie added: "our results show that metformin treatment can slow down the progression of atherosclerosis (arterial thickening) in patients with type 1 diabetes, which means it will become a strong case that metformin can be used as a long-term strategy to reduce the risk of heart disease in patients with type 1 diabetes, and reflect metformin in 2 The application in patients with type diabetes " The main goal of this trial is to test whether metformin (added to standard insulin treatment) twice a day for three years can reduce the risk of heart disease and increased cardiovascular disease in patients over 40 years old with long-term type 1 diabetes 428 patients from the UK, the US, Australia, Canada, Denmark and the Netherlands had a history of type 1 diabetes for 5 years or more The 428 patients were randomly assigned, 219 of whom received metformin and 209 received placebo It took three years to draw the conclusion Every year, the thickness of the great vessel wall (common carotid artery) was measured by the superbirth screening (http://www.chemdrug.com/sell/76/) as a marker of heart disease, and the important secondary parameters related to body weight, insulin dose and cholesterol level were observed Karen Addington, chief executive of type 1 diabetes charity JDRF, who led the study, said: "people with type 1 diabetes live longer and healthier lives (http://www.chemdrug.com/article/7/) However, complications such as heart disease remain a concern for many families " "We are committed to eradicating type 1 diabetes and its complications The findings of this study are very important Through these findings, we can find some easily available drugs, such as metformin, to ensure that the life of patients with type 1 diabetes is healthier and longer " Article: the effect of metformin on cardiovascular and metabolism in patients with type 1 diabetes mellitus (remove): a double-blind, randomized, placebo-controlled clinical trial was published in the lancet diabetes and endocrinology The study was funded by JDRF, a charity dedicated to research, treatment and prevention of type 1 diabetes.